Literature DB >> 18446428

Approaches to handling pharmacodynamic baseline responses.

Chantaratsamon Dansirikul1, Hanna E Silber, Mats O Karlsson.   

Abstract

A few approaches for handling baseline responses are available for use in pharmacokinetic (PK)-pharmacodynamic (PD) analysis. They include: (method 1-B1) estimation of the typical value and interindividual variability (IIV) of baseline in the population, (B2) inclusion of the observed baseline response as a covariate acknowledging the residual variability, (B3) a more general version of B2 as it also takes the IIV of the baseline in the population into account, and (B4) normalization of all observations by the baseline value. The aim of this study was to investigate the relative performance of B1-B4. PD responses over a single dosing interval were simulated from an indirect response model in which a drug acts through stimulation or inhibition of the response according to an Emax model. The performance of B1-B4 was investigated under 22 designs, each containing 100 datasets. NONMEM VI beta was used to estimate model parameters with the FO and the FOCE method. The mean error (ME, %) and root mean squared error (RMSE, %) of the population parameter estimates were computed and used as an indicator of bias and imprecision. Absolute ME (|ME|) and RMSE from all methods were ranked within the same design, the lower the rank value the better method performance. Average rank of each method from all designs was reported. The results showed that with B1 and FOCE, the average of |ME| and RMSE across all typical individual parameters and all conditions was 5.9 and 31.8%. The average rank of |ME| for B1, B2, B3, and B4 was 3.7, 3.8, 3.3, and 5.2 for the FOCE method, and 4.6, 4.3, 4.7, and 6.4 for the FO method. The smallest imprecision was noted with the use of B1 (rank of 3.1 for FO, and 2.9 for FOCE) and increased, in order, with B3 (3.9-FO and 3.6-FOCE), B2 (4.8-FO; 4.7-FOCE), and B4 (6.4-FO; 6.5-FOCE). We conclude that when considering both bias and imprecision B1 was slightly better than B3 which in turn was better than B2. Differences between these methods were small. B4 was clearly inferior. The FOCE method led to a smaller bias, but no marked reduction in imprecision of parameter estimates compared to the FO method.

Entities:  

Mesh:

Year:  2008        PMID: 18446428     DOI: 10.1007/s10928-008-9088-2

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  13 in total

1.  Role of baseline parameters in determining indirect pharmacodynamic responses.

Authors:  Y N Sun; W J Jusko
Journal:  J Pharm Sci       Date:  1999-10       Impact factor: 3.534

2.  Consideration of endogenous backgrounds in pharmacokinetic analyses: a simulation study.

Authors:  F Schindel
Journal:  Eur J Clin Pharmacol       Date:  2000-12       Impact factor: 2.953

3.  A comparison of the bioequivalence of two formulations of epoetin alfa after subcutaneous injection.

Authors:  Akashi Togawa; Takanori Tanaka; Satoru Nagashima; Hiroyuki Keta; Yasue Kobayashi; Yasuhiro Nishikawa; Masanobu Yanai; Hideji Tanaka
Journal:  Br J Clin Pharmacol       Date:  2004-09       Impact factor: 4.335

4.  PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.

Authors:  Lars Lindbom; Pontus Pihlgren; E Niclas Jonsson; Niclas Jonsson
Journal:  Comput Methods Programs Biomed       Date:  2005-09       Impact factor: 5.428

5.  An integrated model for glucose and insulin regulation in healthy volunteers and type 2 diabetic patients following intravenous glucose provocations.

Authors:  Hanna E Silber; Petra M Jauslin; Nicolas Frey; Ronald Gieschke; Ulrika S H Simonsson; Mats O Karlsson
Journal:  J Clin Pharmacol       Date:  2007-09       Impact factor: 3.126

6.  The population pharmacokinetics of recombinant- and urinary-human follicle stimulating hormone in women.

Authors:  M O Karlsson; J R Wade; E Loumaye; A Munafo
Journal:  Br J Clin Pharmacol       Date:  1998-01       Impact factor: 4.335

7.  Comparison of four basic models of indirect pharmacodynamic responses.

Authors:  N L Dayneka; V Garg; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1993-08

8.  Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers.

Authors:  Rohini Ramakrishnan; Wing K Cheung; Mary C Wacholtz; Neil Minton; William J Jusko
Journal:  J Clin Pharmacol       Date:  2004-09       Impact factor: 3.126

9.  Pharmacokinetic/pharmacodynamic models for the depletion of Vbeta5.2/5.3 T cells by the monoclonal antibody ATM-027 in patients with multiple sclerosis, as measured by FACS.

Authors:  Per-Henrik Zingmark; Charlotte Edenius; Mats O Karlsson
Journal:  Br J Clin Pharmacol       Date:  2004-10       Impact factor: 4.335

10.  Population pharmacodynamic analysis of octreotide in acromegalic patients.

Authors:  Emmanuelle Comets; France Mentré; Peter Grass; Ryosei Kawai; Peter Marbach; Jacky Vonderscher
Journal:  Clin Pharmacol Ther       Date:  2003-01       Impact factor: 6.875

View more
  33 in total

1.  Does Older Age Lead to Higher Risk for Neutropenia in Patients Treated with Paclitaxel?

Authors:  Marie-Rose B S Crombag; Stijn L W Koolen; Sophie Wijngaard; Markus Joerger; Thomas P C Dorlo; Nielka P van Erp; Ron H J Mathijssen; Jos H Beijnen; Alwin D R Huitema
Journal:  Pharm Res       Date:  2019-10-15       Impact factor: 4.200

2.  Optimization of the intravenous glucose tolerance test in T2DM patients using optimal experimental design.

Authors:  Hanna E Silber; Joakim Nyberg; Andrew C Hooker; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-06-25       Impact factor: 2.745

3.  Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models.

Authors:  Martin Bergstrand; Andrew C Hooker; Johan E Wallin; Mats O Karlsson
Journal:  AAPS J       Date:  2011-02-08       Impact factor: 4.009

4.  Modeling delayed drug effect using discrete-time nonlinear autoregressive models: a connection with indirect response models.

Authors:  Xu Steven Xu; Hui Wang; An Vermeulen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-03-31       Impact factor: 2.745

5.  Modelling of neutrophil dynamics in children receiving busulfan or treosulfan for haematopoietic stem cell transplant conditioning.

Authors:  Belén P Solans; Robert Chiesa; Bilyana Doncheva; Helen Prunty; Paul Veys; Iñaki F Trocóniz; Joseph F Standing
Journal:  Br J Clin Pharmacol       Date:  2020-03-03       Impact factor: 4.335

6.  Dose finding by concentration-response versus dose-response: a simulation-based comparison.

Authors:  Alienor Berges; Chao Chen
Journal:  Eur J Clin Pharmacol       Date:  2013-02-06       Impact factor: 2.953

7.  Population pharmacokinetics of human antithrombin concentrate in paediatric patients.

Authors:  Brady S Moffett; Rosa Diaz; Marianne Galati; Donald Mahoney; Jun Teruya; Donald L Yee
Journal:  Br J Clin Pharmacol       Date:  2017-08-11       Impact factor: 4.335

8.  Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies.

Authors:  Elena Soto; Ron J Keizer; Iñaki F Trocóniz; Alwin D R Huitema; Jos H Beijnen; Jan H M Schellens; Jantien Wanders; Josep María Cendrós; Rosendo Obach; Concepción Peraire; Lena E Friberg; Mats O Karlsson
Journal:  Invest New Drugs       Date:  2010-05-07       Impact factor: 3.850

9.  Placebo effect model in asthma clinical studies: longitudinal meta-analysis of forced expiratory volume in 1 second.

Authors:  Xipei Wang; Dewei Shang; Jakob Ribbing; Yupeng Ren; Chenhui Deng; Tianyan Zhou; Feng Guo; Wei Lu
Journal:  Eur J Clin Pharmacol       Date:  2012-03-02       Impact factor: 2.953

10.  Development of a placebo effect model combined with a dropout model for bipolar disorder.

Authors:  Wan Sun; Thomas P Laughren; Hao Zhu; Guenther Hochhaus; Yaning Wang
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-03-02       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.